13
In our recent meta-analysis on antibiotic ecotoxicity data published in 14 Environment International (Le Page et al. 2017) we suggest that because of the 15 great diversity in species sensitivity, environmental risk assessment (ERA) 16 would be improved by testing a more diverse range of bacteria (including both 17 environmental bacteria and clinically relevant bacteria (CRB)). We also conclude 18 that tests on antibiotics should consider endpoints of relevance to ecosystem 19 function. Comparing the protection goals for environmental heath with those for 20 human health (protection against antimicrobial resistance (AMR) development) 21
we, furthermore, identify that neither protection goal is always protective of the 22 other whilst using current methodologies (with surrogate endpoints for each 23 goal and very limited bacterial biodiversity tested); supporting the need for both 24 in any comprehensive health protection system for antibiotics. 25
26
In a correspondence to our paper Bengtsson-Palme and Larsson (2018) point 27 out a bias in our sensitivity analysis favouring environmental bacteria (including 28 cyanobacteria). We acknowledge this, but equally in this correspondence we 29 challenge some of their points made on how this impacts on the significance of 30 our data. We also address points relating to the lack of clarity on protection goals 31 for antibiotics in the discussion of our paper and discuss what data are most 32 suitable for establishing those protection goals. We emphasise that the main 33 conclusion drawn from our original paper has not changed and we maintain that 34 a holistic approach including both environmental health and resistance selection 35 is required to drive an effective overall protection limit for antibiotics. 36 response curve (concentration with no inhibition). In some cases therefore CRB 46 may be more sensitive than environmental bacteria than our analysis suggests. 47
However, it should be highlighted that this doesn't necessarily mean that 48 environmental bacteria will not represent the most sensitive taxa for individual 49 antibiotics. This is because, in the first instance, in the cases where 50 environmental bacteria were more sensitive by an order of magnitude or more 51 compared with CRB in our analysis, environmental bacteria are likely to be 52 comparable, if not more sensitive to those antibiotics. In our meta analysis this 53 would be the case for 6 out of 24 antibiotics (including azithromycin and 54 ampicillin). Secondly, very large differences in sensitivity can occur between 55 different species of bacteria (our meta analysis showed sensitivity spanned five 56 orders of magnitude in 8 species cyanobacteria exposed to ampicillin) and 57 because of the far greater species number and diversity tested in CRB compared 58 with environmental bacteria there is likely to be a sensitivity bias in favour of 59 CRB. The size-adjusted MIC value used as our comparative endpoint for CRB was 60 calculated from the MICs of up to 70 species in up to 5 families (Bengtsson-Palme 61 and Larsson 2016). In stark contrast to CRB, cyanobacteria antibiotic test data were generally derived from only one or two species giving far greater 63 uncertainty in the sensitivity calculation for this group. health concerns are generally the main driving force for antibiotic protection 88 goals but they also agree with our conclusions that a holistic approach that 89 considers both environmental health and AMR should be taken. The meta 90 analysis shows that for some antibiotics the environmental protection limits may 91 be lower than the protection limits predicted for AMR (using current 92 methodologies and surrogate endpoints for biodiversity and AMR). To illustrate 93 this, here (Fig 1) we compare the PNECr determined using the size-adjusted MIC 94 data (Bengtsson-Palme and Larsson 2016) and PNECsw calculated from the 95 lowest NOEC in our meta analysis with the PNECfw (PNEC in freshwater) 96 determined for the 5 antibiotics in the European commission environmental 97 quality standards watch list (Carvalho et al. 2015) . In each case the PNECr 98 represents the highest PNEC for each antibiotic (i.e. is least protective as a 99 whole). pollution for environmental health is more of a localised impact, whereas AMR 113 has a wider and more pervasive global significance, directing stakeholders 114 towards the need for two different protection targets determined from 115 appropriate data and methodologies. We still maintain however, that an overall 116 protection limit should protect both environmental and human health. 117
Environmental protection and associated legislation differs across countries, but 118 equally there is a social responsibility to ensure that product provenance is 119 conducted to the highest possible levels. 120
Discharge limit 122
In response to stakeholder calls to address the risk of antibiotics released from 123 manufacturing operations, which currently sits outside of the regulatory ERA 124 framework, in our original paper we proposed an interim production discharge 125 limit of 100 ng/L for each antibiotic, to be applied in the mixing zone to both 126 protect environmental bacteria populations and reduce the risk of AMR 127 development. This interim limit recognised that (i) because most antibiotics 128
were authorised before the current guidelines came into force, many either lack 129 or have very limited ecotoxicology data, and (ii) the need to establish science-130 based limits in the absence of such data. We were explicit in our paper to point 131 out, however, that as sufficient data become available for mode of action relevant 132 species we support the use of higher or lower protection limits based on these 133 empirical data. Bengtsson-Palme and Larsson (2018) questioned this 134 conservative limit for antibiotics because it may incur higher manufacturing 135 costs through the need for infrastructure investment to reduce discharges and 136 based on the fact that some antibiotics have relatively low toxicity and do not 137 logistics for antibiotic supply can be extremely complex with many suppliers 157 manufacturing a whole range of antibiotics for numerous contractors and there 158 can be language barriers and many suppliers lack the expertise to determine safe 159 concentrations for themselves. In this case the use of a single interim limit has 160 practical as well as scientific value. It may help remove conflicting limits (e.g. 161
where two contractors provide different safe values or no level of protection), 162 and minimise confusion amongst the pharmaceutical industry and their 163 suppliers in the absence of data. 164 165
